Evidence map›Paper›PMID 24729929›Full record

ArticleJournal of AIDS and HIV research (Online)2012

Inclusion of South African adolescents in HIV vaccine trials.

David H Adler

Abstract read
In one paragraph

Article in Journal of AIDS and HIV research (Online), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David H AdlerDepartments of Emergency Medicine and Community and Preventive Medicine, University of Rochester, Rochester, NY, USA. david_adler@urmc.rochester.edu . Tel: 585-463-2945.

Funding

Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Post-Vacc. HPV Genotype Distr. Among HIV+ and HIV- Young Women in S. AfricaK23AI077759 · NIAID · UNIVERSITY OF ROCHESTER · PI ADLER, DAVID H · 2010 to 2014
$627k
NIAID NIH HHS K23 AI077759NIAID NIH HHS P30 AI078498
6 · The paper itself

Abstract

South Africa has more people living with HIV than any other nation. The HIV epidemic in South Africa is being driven by new infections among adolescents. Inclusion of adolescents in HIV vaccine trials is essential for successful vaccine development, however, recruitment and retention of at-risk South African adolescents into these trials poses a number of legal, ethical and operational challenges. This article discusses the South African ethico-legal context in which future adolescent HIV vaccine trials would be conducted followed by a review of available data regarding strategies for recruitment into these trials and retention of trial participants.

Indexed as

AdolescentHIV vaccine trialrecruitmentretentionSouth Africa

Identifiers

PMID24729929
PMCPMC3983992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.